letrozole has been researched along with Ovarian Neoplasms in 32 studies
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Letrozole is a proven, potent aromatase inhibitor, extensively tested and used in the treatment of ER positive breast cancer." | 5.51 | Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial. ( Bommer, C; du Bois, A; Dutilh, G; Heinzelmann-Schwarz, V; Klar, M; Kurzeder, C; Marth, C; McLaughlin, PMJ; Reuss, A; Schade-Brittinger, C; Vetter, M; Zwimpfer, TA, 2022) |
| "We performed ovarian stimulation in 126 women with breast cancer by using letrozole and gonadotropins for the purpose of fertility preservation by embryo or oocyte cryopreservation." | 3.76 | Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. ( Babayev, SN; Barad, D; Kim, JY; Oktay, K, 2010) |
| "The letrozole dose was fixed at 2." | 2.73 | A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. ( Arya, N; Chu, QS; Cianfrocca, ME; Fleming, RA; Gale, M; Goldstein, LJ; Koch, KM; Loftiss, J; Murray, N; Pandite, L; Paul, E; Rowinsky, EK, 2008) |
| "Corresponding mRNA in ovarian cancer cell lines treated with 17beta-estradiol (E2) was measured by quantitative RT-PCR." | 2.73 | Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. ( Cameron, DA; Langdon, SP; MacLeod, K; Smyth, JF; Walker, G; Williams, AR, 2007) |
| "Letrozole was administered at a dose of 2." | 2.73 | Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. ( Coleman, RL; Deavers, M; Gershenson, DM; Kavanagh, JJ; Levenback, C; Milam, MR; Ramirez, PT; Schmeler, KM; Slomovitz, BM; Smith, JA, 2008) |
| "Letrozole treatment was generally well tolerated." | 2.71 | Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. ( Dimopoulos, MA; Efstathiou, E; Grimani, I; Hamilos, G; Markaki, S; Papadimitriou, CA; Siapkaras, J; Vlachos, G; Zorzou, M, 2004) |
| "Letrozole, which has a favorable toxicity profile, seems to assure a prolonged recurrence-free interval, particularly when used as maintenance treatment, in low grade serous ovarian cancer; in recurrent cases it had also led to prolonged disease control." | 2.66 | Letrozole in the management of advanced ovarian cancer: an old drug as a new targeted therapy. ( De Felice, F; Ergasti, R; Fagotti, A; Marchetti, C; Scambia, G, 2020) |
| "Tamoxifen was prescribed in 94% of cases." | 1.51 | Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study. ( Åvall-Lundqvist, E; Bagge, E; Beiron, U; Malander, S; Rosenberg, P, 2019) |
| "Letrozole was administered post operatively in 55." | 1.46 | Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? ( Armstrong, DK; Bergstrom, J; DeBernardo, R; Fader, AN; Gaillard, S; Jernigan, A; Levinson, KL; Michener, C; Ricci, S; Roche, KL; Rose, PG; Shih, IM; Stone, RL; Tanner, EJ; Wang, TL; Wethingon, S; Yang, B; Zhang, G, 2017) |
| "Letrozole was effective for ovarian cancers with abundant expression of ERα." | 1.40 | Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice. ( Hirakawa, H; Mizunuma, H; Yokoyama, Y; Yoshida, H, 2014) |
| "The etiology of ovarian epithelial cancer is poorly understood, mainly due to the lack of an appropriate experimental model for studying the onset and progression of this disease." | 1.40 | Dysregulated estrogen receptor signaling in the hypothalamic-pituitary-ovarian axis leads to ovarian epithelial tumorigenesis in mice. ( Bagchi, IC; Bagchi, MK; Haschek, WM; Kannan, A; Laws, MJ; Pawar, S, 2014) |
| "Blepharitis was noted in 68 of 82 eyes (73%), decreased or poor tear function in 24 eyes (29%), conjunctival injection in 18 eyes (22%) and superficial punctate keratitis in 12 eyes (29%)." | 1.39 | Dry eye syndrome in aromatase inhibitor users. ( Hammersmith, KM; Nagra, PK; Nottage, JM; Rapuano, CJ; Turaka, K, 2013) |
| "In patients with breast cancer and co-existing pleural effusions, ascites and adnexal masses, the probability of disseminated disease is high." | 1.35 | A case of Meigs syndrome mimicking metastatic breast carcinoma. ( Al Mufti, R; Behranwala, K; Hadjiminas, DJ; Lanitis, S; Sivakumar, S; Zacharakis, E, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (34.38) | 29.6817 |
| 2010's | 17 (53.13) | 24.3611 |
| 2020's | 4 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Zhuang, Y | 1 |
| Zhang, S | 1 |
| Liu, Y | 1 |
| Yang, H | 1 |
| McLaughlin, PMJ | 1 |
| Klar, M | 1 |
| Zwimpfer, TA | 1 |
| Dutilh, G | 1 |
| Vetter, M | 2 |
| Marth, C | 1 |
| du Bois, A | 1 |
| Schade-Brittinger, C | 1 |
| Reuss, A | 1 |
| Bommer, C | 1 |
| Kurzeder, C | 1 |
| Heinzelmann-Schwarz, V | 2 |
| Marchetti, C | 1 |
| De Felice, F | 1 |
| Ergasti, R | 1 |
| Scambia, G | 1 |
| Fagotti, A | 1 |
| Nica, A | 1 |
| Lee, JYJ | 1 |
| Hong, NL | 1 |
| May, T | 1 |
| Colon-Otero, G | 1 |
| Weroha, SJ | 1 |
| Foster, NR | 1 |
| Haluska, P | 1 |
| Hou, X | 1 |
| Wahner-Hendrickson, AE | 1 |
| Jatoi, A | 1 |
| Block, MS | 1 |
| Dinh, TA | 1 |
| Robertson, MW | 1 |
| Copland, JA | 1 |
| George, A | 1 |
| McLachlan, J | 1 |
| Tunariu, N | 1 |
| Della Pepa, C | 1 |
| Migali, C | 1 |
| Gore, M | 1 |
| Kaye, S | 1 |
| Banerjee, S | 1 |
| Fader, AN | 1 |
| Bergstrom, J | 1 |
| Jernigan, A | 1 |
| Tanner, EJ | 1 |
| Roche, KL | 1 |
| Stone, RL | 1 |
| Levinson, KL | 1 |
| Ricci, S | 1 |
| Wethingon, S | 1 |
| Wang, TL | 1 |
| Shih, IM | 1 |
| Yang, B | 1 |
| Zhang, G | 1 |
| Armstrong, DK | 1 |
| Gaillard, S | 1 |
| Michener, C | 1 |
| DeBernardo, R | 1 |
| Rose, PG | 1 |
| Assi, T | 1 |
| Kourie, HR | 2 |
| El Rassy, E | 1 |
| Moussa, T | 1 |
| Kattan, J | 2 |
| Knipprath Mészaros, A | 1 |
| Stadlmann, S | 1 |
| Jacob, F | 1 |
| Schoetzau, A | 1 |
| Russell, K | 1 |
| Friedlander, M | 1 |
| Singer, G | 1 |
| Stanley, B | 1 |
| Hollis, RL | 1 |
| Nunes, H | 1 |
| Towler, JD | 1 |
| Yan, X | 1 |
| Rye, T | 2 |
| Dawson, C | 1 |
| Mackean, MJ | 2 |
| Nussey, F | 1 |
| Churchman, M | 1 |
| Herrington, CS | 1 |
| Gourley, C | 2 |
| Bagge, E | 1 |
| Beiron, U | 1 |
| Malander, S | 1 |
| Rosenberg, P | 1 |
| Åvall-Lundqvist, E | 1 |
| Antoun, J | 1 |
| Sleilaty, F | 1 |
| Hirakawa, H | 1 |
| Yokoyama, Y | 1 |
| Yoshida, H | 1 |
| Mizunuma, H | 1 |
| Laws, MJ | 1 |
| Kannan, A | 1 |
| Pawar, S | 1 |
| Haschek, WM | 1 |
| Bagchi, MK | 1 |
| Bagchi, IC | 1 |
| Livshits, MA | 1 |
| Vasil'ev, BV | 1 |
| Guseĭnov, KD | 1 |
| Keskin, U | 1 |
| Ercan, CM | 1 |
| Yilmaz, A | 1 |
| Babacan, A | 1 |
| Korkmaz, C | 1 |
| Duru, NK | 1 |
| Ergun, A | 1 |
| van Meurs, HS | 1 |
| van der Velden, J | 1 |
| Buist, MR | 1 |
| van Driel, WJ | 1 |
| Kenter, GG | 1 |
| van Lonkhuijzen, LR | 1 |
| Yazigi, R | 1 |
| Rodríguez, T | 1 |
| Buckel, E | 1 |
| Wash, A | 1 |
| Gershenson, DM | 2 |
| Bodurka, DC | 1 |
| Coleman, RL | 2 |
| Lu, KH | 1 |
| Malpica, A | 1 |
| Sun, CC | 1 |
| Chu, QS | 1 |
| Cianfrocca, ME | 1 |
| Goldstein, LJ | 1 |
| Gale, M | 1 |
| Murray, N | 1 |
| Loftiss, J | 1 |
| Arya, N | 1 |
| Koch, KM | 1 |
| Pandite, L | 1 |
| Fleming, RA | 1 |
| Paul, E | 1 |
| Rowinsky, EK | 1 |
| Lanitis, S | 1 |
| Sivakumar, S | 1 |
| Behranwala, K | 1 |
| Zacharakis, E | 1 |
| Al Mufti, R | 1 |
| Hadjiminas, DJ | 1 |
| Korach, J | 1 |
| Perri, T | 1 |
| Beiner, M | 1 |
| Davidzon, T | 1 |
| Fridman, E | 1 |
| Ben-Baruch, G | 1 |
| Oktay, K | 1 |
| Kim, JY | 1 |
| Barad, D | 1 |
| Babayev, SN | 1 |
| Turaka, K | 1 |
| Nottage, JM | 1 |
| Hammersmith, KM | 1 |
| Nagra, PK | 1 |
| Rapuano, CJ | 1 |
| Bowman, A | 1 |
| Gabra, H | 2 |
| Langdon, SP | 4 |
| Lessells, A | 1 |
| Stewart, M | 2 |
| Young, A | 1 |
| Smyth, JF | 4 |
| Papadimitriou, CA | 1 |
| Markaki, S | 1 |
| Siapkaras, J | 1 |
| Vlachos, G | 1 |
| Efstathiou, E | 1 |
| Grimani, I | 1 |
| Hamilos, G | 1 |
| Zorzou, M | 1 |
| Dimopoulos, MA | 1 |
| Cunat, S | 1 |
| Rabenoelina, F | 1 |
| Daurès, JP | 1 |
| Katsaros, D | 1 |
| Sasano, H | 1 |
| Miller, WR | 1 |
| Maudelonde, T | 1 |
| Pujol, P | 1 |
| Walker, G | 3 |
| MacLeod, K | 2 |
| Williams, AR | 3 |
| Cameron, DA | 2 |
| Stevenson, A | 1 |
| Nafussi, AA | 1 |
| Rye, R | 1 |
| McCurdy, J | 1 |
| Mano, M | 1 |
| Reed, N | 1 |
| McMahon, T | 1 |
| Vasey, P | 1 |
| Raj Pandey, K | 1 |
| Ramirez, PT | 1 |
| Schmeler, KM | 1 |
| Milam, MR | 1 |
| Slomovitz, BM | 1 |
| Smith, JA | 1 |
| Kavanagh, JJ | 1 |
| Deavers, M | 1 |
| Levenback, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).[NCT04111978] | Phase 3 | 540 participants (Anticipated) | Interventional | 2020-11-05 | Recruiting | ||
| PHASE III RANDOMIZED CONTROL CASE STUDY OF LETROZOLE IN WOMEN WITH HEAVILY PRETREATED OVARIAN CANCER (MITO 32)[NCT04421547] | Phase 3 | 236 participants (Anticipated) | Interventional | 2020-06-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for letrozole and Ovarian Neoplasms
| Article | Year |
|---|---|
Letrozole in the management of advanced ovarian cancer: an old drug as a new targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Clinical Trials, Phase II as T | 2020 |
Letrozole in the management of advanced ovarian cancer: an old drug as a new targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Clinical Trials, Phase II as T | 2020 |
Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Fertility Preservation; H | 2014 |
Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Fertility Preservation; H | 2014 |
8 trials available for letrozole and Ovarian Neoplasms
| Article | Year |
|---|---|
Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as | 2022 |
Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as | 2022 |
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.
Topics: Administration, Oral; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhib | 2017 |
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.
Topics: Administration, Oral; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhib | 2017 |
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Fem | 2008 |
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Fem | 2008 |
CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; C | 2002 |
CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; C | 2002 |
Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; CA-1 | 2004 |
Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; CA-1 | 2004 |
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; CA-125 Antigen; Estrogen Receptor Modulators; Fem | 2007 |
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; CA-125 Antigen; Estrogen Receptor Modulators; Fem | 2007 |
Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen | 2007 |
Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen | 2007 |
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Disease Progression; Drug Resistan | 2008 |
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Disease Progression; Drug Resistan | 2008 |
22 other studies available for letrozole and Ovarian Neoplasms
| Article | Year |
|---|---|
GnRHa as a treatment for letrozole-resistant recurrent adult granulosa cell tumors: A case report.
Topics: Female; Gonadotropin-Releasing Hormone; Granulosa Cell Tumor; Humans; Letrozole; Middle Aged; Ovaria | 2021 |
GnRHa as a treatment for letrozole-resistant recurrent adult granulosa cell tumors: A case report.
Topics: Female; Gonadotropin-Releasing Hormone; Granulosa Cell Tumor; Humans; Letrozole; Middle Aged; Ovaria | 2021 |
Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysi | 2021 |
Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysi | 2021 |
The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoma; Femal | 2017 |
The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoma; Femal | 2017 |
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; | 2017 |
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; | 2017 |
Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Granulosa Cell T | 2017 |
Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Granulosa Cell T | 2017 |
Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Cystadenocarcinoma, Serous; Datasets as Topic; D | 2018 |
Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Cystadenocarcinoma, Serous; Datasets as Topic; D | 2018 |
Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; CA-125 Antigen; Cystadenocarcinoma, | 2019 |
Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; CA-125 Antigen; Cystadenocarcinoma, | 2019 |
Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase In | 2019 |
Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase In | 2019 |
Letrozole efficacy in the treatment of granulosa cell tumor of the ovary: a case report.
Topics: Antineoplastic Agents; Female; Granulosa Cell Tumor; Humans; Letrozole; Middle Aged; Nitriles; Ovari | 2013 |
Letrozole efficacy in the treatment of granulosa cell tumor of the ovary: a case report.
Topics: Antineoplastic Agents; Female; Granulosa Cell Tumor; Humans; Letrozole; Middle Aged; Nitriles; Ovari | 2013 |
Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase; Aromatase I | 2014 |
Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase; Aromatase I | 2014 |
Dysregulated estrogen receptor signaling in the hypothalamic-pituitary-ovarian axis leads to ovarian epithelial tumorigenesis in mice.
Topics: Animals; Carcinogenesis; Carcinoma, Ovarian Epithelial; Estrogen Receptor alpha; Estrogens; Female; | 2014 |
Dysregulated estrogen receptor signaling in the hypothalamic-pituitary-ovarian axis leads to ovarian epithelial tumorigenesis in mice.
Topics: Animals; Carcinogenesis; Carcinoma, Ovarian Epithelial; Estrogen Receptor alpha; Estrogens; Female; | 2014 |
[The use of letrozole in ovarian cancer].
Topics: Antineoplastic Agents; Aromatase Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurr | 2014 |
[The use of letrozole in ovarian cancer].
Topics: Antineoplastic Agents; Aromatase Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurr | 2014 |
Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuv | 2015 |
Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuv | 2015 |
Ovarian granulosa cell tumour and letrozole: A case report.
Topics: Antineoplastic Agents; Fatal Outcome; Female; Granulosa Cell Tumor; Humans; Letrozole; Liver Neoplas | 2016 |
Ovarian granulosa cell tumour and letrozole: A case report.
Topics: Antineoplastic Agents; Fatal Outcome; Female; Granulosa Cell Tumor; Humans; Letrozole; Liver Neoplas | 2016 |
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Pro | 2017 |
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Pro | 2017 |
A case of Meigs syndrome mimicking metastatic breast carcinoma.
Topics: Antineoplastic Agents; Breast Neoplasms; CA-125 Antigen; Carcinoma, Ductal, Breast; Diagnosis, Diffe | 2009 |
A case of Meigs syndrome mimicking metastatic breast carcinoma.
Topics: Antineoplastic Agents; Breast Neoplasms; CA-125 Antigen; Carcinoma, Ductal, Breast; Diagnosis, Diffe | 2009 |
Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Letrozole; Mid | 2009 |
Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Letrozole; Mid | 2009 |
Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
Topics: Adult; Breast Neoplasms; Female; Genes, BRCA1; Humans; Infertility; Letrozole; Mutation; Nitriles; O | 2010 |
Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
Topics: Adult; Breast Neoplasms; Female; Genes, BRCA1; Humans; Infertility; Letrozole; Mutation; Nitriles; O | 2010 |
Dry eye syndrome in aromatase inhibitor users.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inh | 2013 |
Dry eye syndrome in aromatase inhibitor users.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inh | 2013 |
Aromatase expression in ovarian epithelial cancers.
Topics: Androstadienes; Aromatase; Aromatase Inhibitors; Cell Proliferation; Cysts; Epithelial Cells; Estrog | 2005 |
Aromatase expression in ovarian epithelial cancers.
Topics: Androstadienes; Aromatase; Aromatase Inhibitors; Cell Proliferation; Cysts; Epithelial Cells; Estrog | 2005 |
Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer.
Topics: Antineoplastic Agents; CA-125 Antigen; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Femal | 2007 |
Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer.
Topics: Antineoplastic Agents; CA-125 Antigen; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Femal | 2007 |
Letrozole effective in ovarian cancer.
Topics: Antineoplastic Agents; Female; Humans; Letrozole; Nitriles; Ovarian Neoplasms; Triazoles | 2007 |
Letrozole effective in ovarian cancer.
Topics: Antineoplastic Agents; Female; Humans; Letrozole; Nitriles; Ovarian Neoplasms; Triazoles | 2007 |